|  |  |
| --- | --- |
| **Table S1. Characteristics of patients completing anti HBV prophylaxis** | |
| ***Patients’characteristics*** | ***N=61*** |
| Male, N (%) | 33 (54.1) |
| Age [Years], Median (IQR) | 66 (57-73) |
| Italian Origin, N (%) | 54 (88.5) |
| ***Oncohaematological Diseases, N (%)*** | |
| Non-Hodgkin Lymphoma (NHL) | 22 (36.1) |
| Acute Myeloid Leukemia (AML) | 13 (21.3) |
| Multiple Myeloma (MM) | 8 (13.1) |
| Chronic Lymphocytic Leukemia (CLL) | 6 (9.8) |
| Hodgkin Lymphoma (HL) | 5 (8.2) |
| Acute Lymphocytic Leukemia (ALL) | 3 (4.9) |
| Other Diseasesa | 4 (6.6) |
| ***Immunosuppressive Regimens, N (%)*** | |
| Rituximab | 23 (37.7) |
| Allogenic HSCT | 20 (32.8) |
| Autologous HSCT | 6 (9.8) |
| Other Chemotherapies | 12 (19.7) |
| ***HBV serological profiles*** |  |
| Anti-HBc positive anti-HBs negative, N (%) | 20 (32.8%) |
| Anti-HBc positive anti-HBs positive, N (%) | 41 (67.2%) |
| Anti-HBs titer, Median (IQR) mIU/ml | 165 (47-969) |
| ***Antiviral Prophylaxis*** | |
| Duration of Antiviral Prophylaxis, Median (IQR) Months | 25 (19-39) |
| a Sézary syndrome, Autoimmune haemolytic anaemia, and Mycosis fungoides.  Abbreviation: HSCT, hematopoietic stem cell transplantation; anti-HBs, antibodies against hepatitis B surface antigen; anti-HBc, antibodies against hepatitis B core antigen. | |